Sphere Fluidics raises $2m with more on the way for US expansion
Cambridge cell technology innovator Sphere Fluidics has raised $2 million to accelerate growth across the UK and US but says it will be raising more to underpin further transatlantic expansion.
Sphere Fluidics, which is set to open a new West Coast sales office in the States, is commercialising single cell analysis systems underpinned by its patented picodroplet technology.
It secured funding from several investors including Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket.
As well as geographical expansion the funds will support sales of Sphere’s Cyto-Mine® Single Cell Analysis System.
Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. It can process up to 40 million cells per day, and assesses and isolates those that produce a specific biologic to help streamline workflows and improve throughput in antibody discovery and cell line development.
CEO Frank Craig (pictured above) said: “We are pleased to see such a high level of interest in Sphere Fluidics and receive funding from several leading investors.
“We are making further investment in automating and streamlining our manufacturing processes across our product range to extend our offering and to deliver our high-quality standards and service to more researchers working in biotherapeutic discovery and cell line development across the UK and USA. We will be raising additional funds to expand these capabilities further.”
• Cyto-Mine will be on display in Washington DC at SLAS 2019 from February 2-6 (Booth #1655 and #1429).